Replies to post #133458 on Biotech Values

[DewDiligence]

Europe’s EMA is investigating NVS’ Rasilez for risk of stroke and kidney disease:

http://online.wsj.com/article/SB10001424052970203686204577114711607987168.html

Why bother? In all likelihood, NVS plans to pull the drug voluntarily (#msg-70119323).